Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05514548 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

A Phase 2 study of Diabetic Kidney Disease, sponsored by Inversago Pharma.

Completed
Registry status
Phase 2
Development phase
265
Enrollment target
20
Study locations

NCT05514548: Completed Phase 2 study of Diabetic Kidney Disease, sponsored by Inversago Pharma.

NCT05514548 is a Phase 2 study of Diabetic Kidney Disease that has completed, run by Inversago Pharma. The registered enrollment target is 265 participants, below the 5,178-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05514548, a Phase 2 study of Diabetic Kidney Disease, has completed, sponsored by Inversago Pharma.

COMPLETED
Registry status
Phase 2
Development phase
265 participants
Enrollment target
20
Study locations

Study Summary

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.

Primary Outcome

Measure of UACR at W16 in comparison to baseline to evaluate the effect of INV-202 in participants with diabetic kidney disease (DKD)

Conditions Studied

Diabetic Kidney Disease

Interventions

  • DRUG Placebo
  • DRUG INV-202

Study Locations (20)

California

  • National Institute of Clinical Research, Inc. - Garden Grove
  • National Institute of Clinical Research, Inc - Pomona - Pomona
  • Central Coast Nephrology - Salinas
  • North American Research Institute - San Dimas
  • National Institute of Clinical Research, Inc - Upland - Upland

Florida

  • Research Physicians Network Alliance - Boca Raton
  • ALL Medical Research, LLC - Cooper City
  • South Florida Research Institute - Lauderdale Lakes

Texas

  • North Texas Endocrine Center - Dallas
  • Biopharma Informatic, LLC - Houston
  • Linq Research, LLC - Pearland

Georgia

  • Endocrine Research Solutions, Inc. - Roswell

Illinois

  • Research by Design, LLC - Chicago

Maryland

  • Endocrine and metabolic Consultants - Rockville

Missouri

  • Clinical Research Consultants, LLC - Kansas City

Nevada

  • Palm Research Center, Inc - Las Vegas

Trial Details

FieldValue
Enrollment Target 265 participants
Start Date 2022-10-19
Est. Completion 2024-09-03
Phase Phase 2
Inversago Pharma

1 total trials

What the finished NCT05514548 record still lists

NCT05514548 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, below the 5,178-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05514548 names 20 study sites across 12 states, led by California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT05514548 about?

NCT05514548 is a clinical study titled "Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease". The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.

What is the current status of trial NCT05514548?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2022-10-19. Estimated completion is 2024-09-03.

What conditions does trial NCT05514548 study?

This clinical trial studies the following conditions: Diabetic Kidney Disease.

What interventions are being tested in trial NCT05514548?

The interventions under investigation include: Placebo (DRUG), INV-202 (DRUG).

Who is sponsoring clinical trial NCT05514548?

This trial is sponsored by Inversago Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05514548 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05514548's enrollment target sits among peer trials

265 7th of 23 higher than 17 of 23 other Diabetic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05443126 · 265 participants · Phase 1

    A Study of EP0031 in Patients With Advanced RET-altered Malignancies

  • NCT05470491 · 265 participants · Phase 1

    Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

  • NCT07301905 · 265 participants · NA

    Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI

  • NCT07470853 · 265 participants · Phase 1

    A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05514548, the US trial registry maintained by the National Library of Medicine. NCT05514548 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.